MRNA

MRNA

USD

Moderna Inc. Common Stock

$23.750-0.890 (-3.612%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$24.640

最高

$25.150

最低

$23.710

交易量

13.75M

公司基本面

市值

9.3B

行業

生物科技

國家

United States

交易統計

平均交易量

11.01M

交易所

NMS

貨幣

USD

52週範圍

最低 $23.15當前 $23.750最高 $56.695

相關新聞

CNBC

November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk

Here are five key things investors need to know to start the trading day.

查看更多
November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk
Analyst Upgrades

UBS Maintains Buy on Moderna, Lowers Price Target to $40

UBS analyst Eliana Merle maintains Moderna with a Buy and lowers the price target from $70 to $40.

查看更多
UBS Maintains Buy on Moderna, Lowers Price Target to $40
AccessWire

Moderna Named a Top Employer by Science for Eleventh Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers

查看更多
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
Analyst Upgrades

JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $25

JP Morgan analyst Jessica Fye maintains Moderna with a Underweight and lowers the price target from $26 to $25.

查看更多
JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $25
Analyst Upgrades

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance.

查看更多
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
AccessWire

Moderna to Host Investor Event - Analyst Day

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.The event will include

AccessWire

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patientsCompany does not anticipate any impact to its 2025